Ionis reports third quarter financial results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/26/2026
- Wall Street mixed as Moderna rallies and chips tumble
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
- Needham Starts NeoVolta (NEOV) at Buy
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 39c; Offers F22 Revenue Guidance
November 9, 2022 7:03 AM ESTIonis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.33), $0.39 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $160 million versus the consensus estimate of $145.75 million.
GUIDANCE:
Ionis Pharmaceuticals sees FY2022 revenue of $575 million, versus the consensus of $595... More
